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Summary
In vertebrates, the morphogenetic assembly of the
primitive heart tube requires the medial migration
andmidline fusion of the bilateral myocardial epithelia
[1, 2]. Several mutations that result in abnormal heart-
tube formation have been studied; however, an under-
standing of the underlying molecular and cellular
mechanisms of the migration and fusion of these epi-
thelial sheets is far from complete [1–4]. In a forward
genetic screen to identify genes regulating early ze-
brafish heart development, we identified a mutation
in the 3-hydroxy-3-methylglutaryl-Coenzyme A reduc-
tase 1b (hmgcr1b) gene that affects myocardial migra-
tion to themidline and subsequent heart-tubemorpho-
genesis. The mutant phenotype can be rescued with
injections ofmevalonate, the direct product of HMGCR
activity. Furthermore, treatment of embryos with phar-
macological inhibitors of isoprenoid synthesis, which
occurs downstream of mevalonate production, re-
sulted in defective heart-tube formation. Interestingly,
in hmgcr1b mutant embryos and embryos treated
with HMGCR inhibitors, both RasCT20-eGFP and
RhoaCT32-eGFP fusion proteins were mislocalized
away from the plasma membrane in embryonic myo-
cardial cells. We conclude that protein prenylation,
acting downstream of Hmgcr1b and possibly through
Ras and, or, Rho signaling, is required for themorpho-
genesis of the myocardial sheets for formation of the
primitive heart tube.
Results and Discussion
A Novel Mutant with Early Heart Morphogenesis
Defects
In order to more thoroughly understand the molecular,
genetic, and cellular mechanisms of early heart forma-
tion, we carried out a forward genetic screen in zebrafish
to identify additional genes regulating early heart devel-
opment. The s617 mutation was originally identified as
causing delayed myocardial migration to the midline.
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Canada.By 24 hr postfertilization (hpf), all s617 mutant embryos
exhibit a thin, midline heart, a thick yolk extension, and
pericardial edema (Figure 1). These defects become
more pronounced by 36 and 48 hpf. Circulation is always
absent in the mutant embryos.
In order to examine the heart phenotype more closely,
we used a transgenic line, Tg(cmlc2:egfp) [5], in which
the cmlc2 promoter drives eGFP expression in the
myocardial cells. We found that 21-somite-stage s617
mutant embryos show delayed migration of the bilateral
myocardial cell populations to the midline compared to
their wild-type siblings (Figures 1F and 1G). By 24 hpf,
the wild-type hearts have jogged to the left (Figure 1H),
whereas s617 mutant hearts remained at the midline
(Figure 1I). The more severely affected mutant embryos
also exhibited a delay in heart tilting and extension (Fig-
ure 1I). By 48 hpf, when wild-type hearts have undergone
looping morphogenesis, s617 mutant hearts were un-
looped, thin midline structures.
Many mutations that cause myocardial migration
defects have been shown to primarily affect endoderm
development [6–11], suggesting that early heart mor-
phogenesis requires an intact endoderm. In order to de-
termine whether the s617 mutation was affecting endo-
derm development, we used a transgenic line in which
the her5 promoter drives eGFP expression in the pha-
ryngeal endoderm (Tg(0.7her5:egfp)ne2067) [12]. No obvi-
ous differences in pharyngeal endoderm development
were observed between mutant embryos and their
wild-type siblings before 24 hpf (Figures 1J and 1K).
These data suggest that endoderm differentiation and
early morphogenesis are unaffected in s617 mutant
embryos.
The s617 Gene Encodes 3-Hydroxy-3-methylglutaryl
coenzyme A reductase 1b
To gain a better molecular understanding of the s617
phenotype, we isolated the s617gene by positional clon-
ing (Figure 2). By using bulk-segregant analysis, we map-
ped the s617 locus to LG21. Fine mapping with 1301 dip-
loid mutant embryos narrowed the s617 genomic region
to a 1.6 cM span between CA repeat markers z6295 and
z7405. Further fine mapping revealed that the s617 locus
was located on the BAC CH211-149I8 (CR318660). One
recombinant and zero recombinant markers were found
in the 50 and 30 UTR regions of thehmgcr1bgene, respec-
tively (Figure 2A). Because HMGCR had been implicated
in regulating germ-cell migration in zebrafish and Dro-
sophila [13, 14], we focused on hmgcr1b as a candidate
for the s617 locus. Sequencing hmgcr1b from s617 mu-
tant embryos revealed a G to A (GGT/GAT) transition
at position 1575 (Figure 2B). This mutation results in an
amino acid change from glycine (Gly) to aspartic acid
(Asp) at codon 497. Interestingly, this glycine residue
lies at a highly conserved position in a region required
for homodimerization or tetramerization of HMGCR (Fig-
ure 2C) [15, 16]. We confirmed that this mutation occurs
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253Figure 1. s617 Mutant Embryos Exhibit an
Early Heart Morphogenesis Defect
(A and B) By 24 hr postfertilization (hpf),
mutant embryos (B) exhibit a slightly thicker
yolk extension (indicated by the arrow) and
pericardial edema (indicated by the arrow-
head) compared to their wild-type siblings
(A).
(C, D, and E) By 30 (C and D) and 48 (E) hpf,
the thick yolk extension (indicated by the ar-
row) and edema (indicated by the arrowhead)
have become more obvious in mutant em-
bryos. Lateral views with anterior to the left
are shown in (A)–(E).
(F and G) Compared to a fused midline heart
in wild-type embryos (F) at the 21-somite
stage (19.5 hpf), the myocardial epithelia in
s617 mutant embryos (G) exhibit delayed
medial migration.
(H and I) At 24 hpf, wild-type hearts (H) extend
toward the left side of the embryo. In con-
trast, s617 mutant hearts (I) usually remain
at the midline and are delayed in their
formation.
(J and K) Anterior endoderm morphogenesis,
as assayed by Tg(0.7her5:egfp)ne2067 expres-
sion in the wild-type (J) and mutant (K),
appears unaffected at the 22-somite stage.
Dorsal views with anterior to the left are
shown in (F)–(K).at the genomic level in s617 mutant embryos by se-
quencing the relevant genomic region (data not shown).
To further test whether a defect in hmgcr1b is suffi-
cient to cause a heart morphogenesis phenotype, we
injected a morpholino antisense oligo designed against
the hmgcr1b initiation ATG sequence into one-cell-
stage embryos. Morpholino injections resulted in a phe-
nocopy of the s617 mutation, including pericardial
edema, thick yolk extension, and heart morphogenesis
defects. However, as expected based on the fact that
hmgcr1b mRNA is present maternally [13], more severe
defects were common when the MO was injected at high
doses (10 ng/embryo), with axis defects and frequent
embryonic death by 24 hpf. Lower doses (5 ng/embryo)
caused slightly less severe phenotypes that more
closely resembled the s617 phenotype (Figure 2D).
In order to further establish whether the s617 mutant
heart defects are due to a mutation in hmgcr1b, we
treated embryos with statins, specific inhibitors of
HMGCRs, and were able to phenocopy the s617 muta-
tion (Figures 2E and 2F). Embryos were soaked in either
10 mM Atorvastatin or 1.2 mM Mevinolin starting at theend of gastrulation. Atorvastatin treatment resulted in
embryos with slightly thicker yolk extensions and kinked
notochord as previously described [13], as well as mid-
line, unlooped hearts (Figure 2E). The heart phenotype
looked very similar to that seen in s617 mutant embryos.
Soaking embryos in Mevinolin resulted in a much more
severe heart and general somatic phenotype: Com-
pressed and straight somites, a short tail, and a thick
yolk extension were present as previously described
[13]. Mevinolin treatments also blocked myocardial cell
migration to the midline, resulting in cardia bifida
(Figure 2F).
To further confirm that HMGCR activity is required for
heart morphogenesis, we injected mevalonate, the di-
rect downstream product of HMGCR, and were able to
rescue the s617 mutant phenotype (Figure 2G). Injection
of 2.3 nl of a 0.5 M mevalonate solution into one-cell-
stage embryos resulted in a rescue of the s617 mutant
phenotype through the first 72 hpf. Embryos were ana-
lyzed at 48 hpf and then genotyped with a restriction
fragment length polymorphism (RFLP) generated by
the s617 mutation. Heart morphogenesis and function,
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254Figure 2. The s617 Gene Encodes 3-Hydroxy-3-methylglutaryl coenzyme A reductase 1b
(A) Genetic map around the s617 locus.
(B) Sequencing of the hmgcr1b cDNA from mutant and wild-type embryos revealed a G to A transition at position 1575, which results in a Gly to
Asp amino acid change at codon 497.
(C) This glycine residue is highly conserved in a region critical for dimerization [15, 16] (# indicates amino acids with a role in homodimer or
tetramer formation).
(D) Injection of an ATG hmgcr1b morpholino phenocopied the s617 mutation.
(E and F) Statin treatments of wild-type embryos also resulted in a phenocopy of the s617 mutation. Lateral views of untreated embryos (top) and
treated embryos (bottom) are shown. The right panels show dorsal views (anterior toward bottom) of treated embryos, with bright field (top) and
Tg(cmlc2:egfp) expression (bottom). (E) shows that embryos soaked in 10 mM Atorvastatin exhibited notochord kinks and a midline heart tube at
28 hpf. (F) shows that embryos soaked in 1.2 mM Mevinolin exhibited a shortened body axis, straight somites, a thick tail extension, and cardia
bifida.
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However, a functioning Hmgcr1b is still required later in
development because rescued mutant embryos devel-
oped edema by 5 dpf and did not survive to adulthood.
Protein Prenylation Is Required for Heart
Morphogenesis
Studies in zebrafish and Drosophila have shown that
germ-cell migration requires protein prenylation, rather
than cholesterol synthesis, downstream of HMGCR
[13, 14]. To determine whether early heart morphogene-
sis also requires the prenylation branch (geranylgerany-
lation and farnesylation of proteins) downstream of me-
valonate production, as well as to differentiate between
the geranylgeranylation and farnesylation pathways,
we treated embryos with pharmacological inhibitors
of geranylgeranyl transferase 1 (GGT1) and farnesyl
transferase (FT).
To test the requirement for GGT1 activity in myocardial
epithelial migration, we injected one- to two-cell-stage
embryos with 2 nl of a 1 mM solution of the GGT1 inhibitor
GGTI-2177 in 25% DMSO. When observed at 48 hpf,
treated embryos exhibited myocardial migration de-
fects, including cardia bifida and partially fused midline
hearts (Figures 3E and 3F). Other phenotypes exhibited
by GTI-2177-treated embryos included pericardial
edema and a thick yolk extension (Figure 3C). These phe-
notypes are similar, but much more severe, than those
exhibited by s617 mutant embryos. Some of the treated
embryos also exhibited other somatic defects, including
cyclopia (20%, n > 50), short curved tails, and kinked no-
tochords (85%). Control injections of 2 nl of 25% DMSO
alone had no effect.
In contrast, treatment of embryos with the FT inhibitor
L-744 resulted in much less severe phenotypes that
more closely resembled those of s617 mutant embryos.
An injection of 2 nl of a 1 mM solution of L-744 into one-
cell-stage embryos resulted in midline hearts similar to
those observed in s617 mutant embryos (Figures 3G
and 3H). Pericardial edema and thick-yolk-extension
phenotypes were also similar to those exhibited by
s617mutant embryos (Figure 3D). Treatment of embryos
with up to 40 mM zaragozic acid, a specific inhibitor of
squalene synthase in the sterol synthesis pathway
downstream of HMGCR [17], resulted in no observable
heart defects (data not shown). The striking similarities
of the phenotypes observed in s617 mutants, statin-
treated, and prenylation-pathway-inhibitor-treated em-
bryos suggest that protein prenylation plays a central
role in the migration of the myocardial epithelia to the
midline. Furthermore, these data indicate that the heart
migration defects in s617 mutant and statin-treated
embryos are primarily caused by a lack of isoprenoid
synthesis downstream of Hmgcr1b activity.
The posttranslational modification of proteins with an
isoprenyl anchor plays an important role during localiza-
tion of many proteins to the plasma membrane [18–20]. A
CAAX motif (C, cysteine; A, aliphatic amino acid; X, any
amino acid) at the carboxyl terminus of proteins is recog-
nized by GGT1 or FT, which then adds the appropriateisoprenyl product to the cysteine residue in the CAAX
motif. In order to test whether mislocalization of prenyla-
tion-mediated, membrane-targeted proteins occurred
in the myocardial cells of embryos deficient in HMGCR
activity, we treated transgenic embryos expressing
RasCT20-eGFP (eGFP fused with the 20 amino acid car-
boxyl terminus of human Ras containing the CAAX motif)
under the cmlc2 promoter (Tg(cmlc2:rasCT20-egfp)s883)
with statins after the 12-somite stage. We observed the
localization of RasCT20-eGFP by using confocal micros-
copy. In untreated embryos, RasCT20-eGFP was local-
ized, as expected, to the plasma membrane of myocar-
dial cells (Figure 4A). In contrast, treatment of embryos
with Atorvastatin resulted in RasCT20-eGFP mislocali-
zation to the nucleus and cytoplasm. Membrane locali-
zation, although not as robust as in untreated embryos,
was still present (Figure 4B). Treatment of embryos
with Mevinolin resulted in a striking mislocalization of
RasCT20-eGFP to the nucleus and cytoplasm (Fig-
ure 4C). Membrane localization was mostly absent, al-
though some membrane localization was retained in a
small number of cells.
Similarly, we tested whether a RhoaCT32-eGFP fusion
protein was mislocalized in statin-treated embryos.
Transient transgenic embryos expressing a fusion pro-
tein consisting of the 32 amino acid carboxyl terminus
of zebrafish Rhoa attached to eGFP under the cmlc2
promoter (Tg(cmlc2:RhoaCT32-egfp)) were generated.
Untreated embryos showed RhoaCT32-eGFP localized
to the membrane of myocardial cells (Figure 4D). In
both Atorvastatin- and Mevinolin-treated embryos,
RhoaCT32-eGFP mislocalized to the cytoplasm (Figures
4E and 4F).
We further examined the localization of the RasCT20-
eGFP fusion protein in s617mutant embryos by generat-
ing s617;Tg(cmlc2:rasCT20-egfp)s883 fish. Compared to
the membrane localization in wild-type sibling embryos
(Figure 4G), s617 mutant embryos exhibited a mislocali-
zation of RasCT20-eGFP to the cytoplasm and nucleus
of myocardial cells (Figure 4H). These results indicate
that Hmgcr1b activity is required for the targeting of
this CAAX box-containing fusion protein to the mem-
branes of the myocardial cells.
Although it is not known whether Rho or Ras mislocal-
ization in myocardial cells contributes to the s617 heart
phenotype, it appears likely that a combination of nor-
mally prenylated proteins are mislocalized, and their nor-
mal function perturbed, in statin-treated and s617 mu-
tant embryos. These experiments further indicate that
protein prenylation plays an important role in early zebra-
fish heart morphogenesis, likely through one or more
isoprenoid-modified proteins, including Ras and RhoA.
Our data show that inhibition of GGT1 results in a much
more severe myocardial migration defect than FT inhibi-
tion does. This stronger phenotype with GGT1 inhibition
implies that one or more proteins, which are normally
modified by geranylgeranylation, may be more critical
for myocardial epithelium migration. Interestingly, Rho
family members, including RhoA, are known to be a
significant target for geranylgeranylation modification(G) Mutant embryos can be rescued by injection of mevalonate into one-cell-stage embryos. Individual embryos were imaged and then geno-
typed with a RFLP caused by the s617 mutation. Mevalonate-injected mutant embryos are indistinguishable from wild-type embryos through the
first 72 hpf.
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way Can Phenocopy the s617 Mutation
(A and B) An uninjected wild-type sibling (A)
and an embryo (B) injected with 2 nl of a
25% DMSO solution.
(C, E, and F) Embryos injected with 2 nl of a 1
mM GGTI-2177 in 25% DMSO exhibited phe-
notypes that ranged from a phenocopy of the
s617 mutation (C) to a much more severe car-
dia bifida and cyclopia phenotype (E and F).
(D, G, and H) Embryos injected with FTI/L744
(2 nl of a 1 mM solution in 25% DMSO) ex-
hibited a milder phenotype, including midline
hearts, pericardial edema, and a thick yolk
extension, similar to the s617 mutant pheno-
type. All embryos shown are at 48 hpf. (A)–
(D) show lateral views with the anterior to
the left. (E)–(H) show ventral views with the
anterior up.[21–25]. Additionally, Rho family members are crucial
regulators of cell migration [26–30] and appear to play
a significant role in heart morphogenesis [31].
HMGCR Activity Is Required Specifically during
Myocardial Cell Migration
In order to determine when HMGCR activity is required
for myocardial epithelial migration, we took advantage
of our ability to inhibit HMGCR at specific times during
development. All embryos were soaked in 10 mM Ator-
vastatin or 1.2 mM Mevinolin beginning at the following
developmental stages: 256 cells, midgastrulation, tail
bud, 9 somites, 15 somites, 20 somites, or 24 hpf, and
the following data are summarized in Table S1 (in the
Supplemental Data available with this article online).
Embryos treated with Atorvastatin from the 256-cell
stage exhibited mild axis defects and partially fused
hearts by 1 dpf. Treatment of embryos starting from
midgastrulation resulted in midline hearts, some reduc-
tion in heart size, and kinked notochords, as previously
described [13]. Treatment of embryos after gastrulation
resulted in wavy or kinked notochords in 28/35 embryos
and delayed, midline hearts in 21/35 embryos (see Fig-
ure 2E). Treatment of 9-somite-stage embryos resulted
in 2/33 hearts showing delayed fusion, 18/33 midline
hearts, and 13/33 wild-type hearts. In embryos treated
after 15 somites, only 7/30 embryos had midline hearts,
whereas most embryos exhibited wild-type hearts. Ator-
vastatin treatments after myocardial migration had
taken place (20 somites) caused no observable heart
defects. Atorvastatin treatments, therefore, reveal a re-
quirement for HMGCR activity before and duringprecardiac mesoderm migration (15–20 somites) for
heart morphogenesis.
We also tested the timing for the requirement of
HMGCR activity for heart morphogenesis with Mevinolin,
another statin that causes stronger somatic phenotypes
than Atorvastatin. Mevinolin treatment of 256-cell-stage
embryos resulted in severe axis defects (14/14), necro-
sis, and embryo death by 1 dpf. Mevinolin treatment be-
ginning during gastrulation resulted in 20/20 embryos
with short axis, straight somites, yolk-extension thicken-
ing, and bifid, reduced hearts. Treatment of embryos
after gastrulation resulted in 35/35 embryos with short
axis, straight somites, thick yolk extension; 30/35 em-
bryos had bifid, reduced hearts (see Figure 2F) and 5/
35 embryos had reduced, midline hearts at 1dpf. By 48
hpf, all of these embryos were dead. Cardia bifida, a thick
yolk extension, a short tail, and straight somites (36/47)
were also observed in embryos treated after 9 somites,
but with an increased survival rate (7/47 dead by 48
hpf). Interestingly, treatment of embryos starting at 15
somites resulted in 25/25 embryos with cardia bifida or
partially fused hearts, as well as short tails, a thick yolk
extension, and pericardial edema. Even embryos treated
as late as 20 somites showed heart migration defects,
including partial fusion and midline hearts. Treatments
after 24 hpf resulted in midline, unlooped hearts and a
slightly thickened yolk extension. These experiments re-
veal a requirement for HMGCR activity for heart morpho-
genesis during the stages that the myocardial epithelia
are migrating and fusing at the midline (15-20 somites).
Subsequent heart morphogenesis (tilting, left-jogging,
and looping) also appears to require HMGCR activity,
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257Figure 4. Mislocalization of Membrane Tar-
geted CAAX Fusion Proteins in Embryos
with Disrupted HMGCR Activity
Statin treatment of embryos results in misloc-
alization of RasCT20-eGFP and RhoaCT32-
eGFP fusion proteins in myocardial cells.
(A) A 48 hpf untreated Tg(cmlc2:rasCT20-
egfp)s883 embryo showing RasCT20-eGFP
localization to the plasma membrane of the
myocardial cells.
(B) Treatment of Tg(cmlc2:rasCT20-egfp)s883
embryos with Atorvastatin starting at the
12-somite stage resulted in RasCT20-eGFP
mislocalization in myocardial cells. Although
RasCT20-eGFP was often mislocalized to
the nucleus and cytoplasm, membrane
RasCT20-eGFP localization was still present
in most cells.
(C) A Tg(cmlc2:rasCT20- egfp)s883 embryo
soaked in Mevinolin exhibited mislocalized
RasCT20-eGFP in the cytoplasm and nu-
cleus. Membrane localization was markedly
reduced.
(D) An untreated 36 hpf transient Tg(cmlc2:
RhoaCT32-egfp) embryo exhibited mem-
brane localization of RhoaCT32-eGFP in
a myocardial cell.
(E) Treatment of transient Tg(cmlc2:
RhoaCT32-egfp) embryos with Atorvastatin
resulted in GFP mislocalization to the cyto-
plasm and nucleus.
(F) Mevinolin treatment also resulted in GFP
mislocalization to the cytoplasm and nucleus.
(G and H) Membrane localization of RasCT20-
eGFP is perturbed in s617 mutant embryos.
Compared to membrane localization in
wild-type sibling embryos (G), s6172/2;
Tg(cmlc2:rasCT20-egfp) embryos exhibit
mislocalization of RasCT20-eGFP in the
cytoplasm and nucleus (H).as revealed by post-19 and 24 hpf Mevinolin treatments.
Although early statin treatment (before 15 somites) re-
veals a requirement for HMGCR activity for both general
embryonic and heart development, only heart develop-
ment is significantly affected in embryos treated after
15 somites. This decoupling of the statin-induced heart
defects from general somatic defects reveals a specific
requirement for HMGCR activity during early vertebrate
heart morphogenesis.
In studies in Drosophila, it was recently reported that
HMGCR activity is required for heart formation [32]. Yi
et al. showed a cell-autonomous requirement for
HMGCR activity, via geranylgeranylation of the G protein
Gg1, in the cardioblasts for their adhesion to pericardial
cells [32]. Our data show a similar requirement for
HMGCR activity for heart morphogenesis in vertebrate
embryos. HMGCR appears to be required in zebrafish
at an earlier step of heart formation, i.e., during the migra-
tion of the myocardial cells to the midline and subse-
quent assembly of the heart tube at the midline. How-
ever, it appears that the insertional allele used in the
Drosophila study is not a null and that a more severe
EMS allele leads to a heart phenotype that could be inter-
preted as a delayed migration or fusion defect ([32],Figure 2B). Alternatively, it is possible that maternally
provided HMGCR activity can sustain heart development
to a later stage in Drosophila than it does in zebrafish.
Conclusion
Our study shows a requirement for HMGCR activity for
the medial migration and fusion of the vertebrate myo-
cardial epithelium, as well as the subsequent tilting
and looping morphogenesis of the heart. HMGCR ap-
pears to function largely through isoprenoid synthesis
and the posttranslational prenylation of proteins in reg-
ulating early heart morphogenesis. We found that GGT1
inhibition resulted in severe myocardial migration de-
fects. Furthermore, statin treatments were found to
cause the striking mislocalization of a Rhoa-GFP fusion
protein in myocardial cells, suggesting that this impor-
tant regulator of the cytoskeleton and cell migration
requires robust HMGCR activity in the myocardial epi-
thelium. These results, together with those recently re-
ported in Drosophila [32], reveal another element in the
regulation of early heart morphogenesis and give us




Zebrafish Strains and Care
Adult and embryonic zebrafish were raised and cared for in accor-
dance with standard laboratory procedures [33]. We used the
following zebrafish mutant and transgenic strains: hmgcr1bs617,
Tg(cmlc2:egfp) [5], Tg(0.7her5:egfp)ne2067 [12], and Tg(cmlc2:
rasCT20-egfp)s883. A mutagenesis screen was carried out in collab-
oration with Herwig Baier’s lab as previously described [34, 35].
Fluorescence and Confocal Microscopy and Analysis
Tg(cmlc2:egfp) and Tg(0.7her5:egfp)ne2067 embryos were imaged
live with a Zeiss SteREO Lumar V12 microscope or Zeiss Stemi
SV11 dissecting microscope and a Zeiss AxioCam. Brightfield im-
ages were aquired with a Zeiss Stemi SV11. Other embryos were
fixed overnight at 4C in 4% paraformaldehyde in PBS. Vibratome
sections of embryos were performed with a Leica VT1000S and
mounted on slides in Vectashield (Vector Laboratories) for imaging
on a Zeiss LSM5 Pascal confocal microscope.
Cloning of the hmgcr1b Locus
Zebrafish CA repeat microsatellite primers were obtained from the
Massachusetts General Hospital Zebrafish server website (http://
zebrafish.mgh.harvard.edu). Fine mapping with 1301 diploid mutant
embryos narrowed the region of interested to a single bacterial arti-
ficial chromosome (BAC) CHORI-211 149I8 (CR318660) with a one
recombinant marker and a two recombinant marker flanking a 44
kb region. This BAC was sequenced and assembled by the Sanger
Center Danio rerio Sequencing Project. This region contains two pu-
tative open reading frames (ORFs), hmgcr1b (AI497311) and GPBP
(BC088384), based on GENESCAN gene prediction software [36].
An ATG morpholino to GPBP (Gene-Tools) was injected into one-
cell-stage embryos and caused no obvious phenotype (data not
shown). Subsequently, one and zero recombinant markers were
found in the 50 region and 30 region of the hmgcr1b gene, respec-
tively. The hmgcr1b gene was sequenced from cDNA, and the ge-
netic lesion in hmgcr1b was confirmed by sequencing of genomic
DNA. A restriction fragment length polymorphism (RFLP) introduced
by the s617 mutation was resolved with forward (50-TGTGTGAGG
ATGTGGAGCTT-30) and reverse (50-GACTCACTGTGACGGCTCTG-
30) primers and digested with FokI. (Injection of hmgcr1b mRNA
into wild-type and s617 mutant embryos caused deleterious effects,
a result that precluded rescue experiments by this method.) The
hmgcr1b ATG morpholino (50-TCATCATCATCACGGTCTTCAGTGG-
30) was designed by Gene-Tools, Inc.
Transient Transgenic Embryo Production
The pCS2+ cmlc2:rasCT20-eGFP construct (gift of Le Trinh) was
modified by replacement of the C-term of hras with the C-term of
zebrafish rhoa (rhoaCT32). rhoaCT32 was amplified with the for-
ward+XbaI (50-AGATCTAAAACTAAGGAGGGCGTGAG-30) and re-
verse+BglII (50-TCTAGACCTCCCTCGTTCTTCTCATT-30) primers
on a 2 dpf cDNA library. The pCS2+ cmlc2rhoaCT32-egfp construct
was linearized with SnaB and injected into recently fertilized em-
bryos so that transient transgenic embryos expressing RhoaCT32-
eGFP in myocardial cells could be generated.
Pharmacological Treatment of Embryos
Embryos were soaked in 1.2 mM Mevinolin (Sigma), 10 mM Atorvas-
tatin (Pfizer), or 40 mM Zaragozic acid (Sigma) in embryo water (be-
ginning at the developmental stages indicated). One-cell-stage em-
bryos were injected with 2.3 nl of a 0.5M mevalonate solution or 2 nl
of the FT inhibitor L-744 (CalBiochem) or GGTI inhibitor GGTI-2177
(CalBiochem) at a 1 mM concentration in 25% DMSO.
Supplemental Data
Supplemental Data include one table and can be found with this
article online at http://www.current-biology.com/cgi/content/full/
17/3/252/DC1/.
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